Research reports on mining opportunities | Guolian: Initiating a "buy" rating for Huadong Medicine, with visible results from its innovative transformation.
East China Pharmaceutical (000963): Innovation and Globalization - Two-wheel Drive High Quality Growth
East China Pharmaceutical (000963): Bailing Mining Risk Landed, GLP-1 is about to go overseas
East China Pharmaceutical (000963): Abundant reserves of domestic medical and aesthetic slowing weight loss products
Huadong Pharmaceutical (000963): The performance is in line with expectations, and the industrial profit performance is impressive
Deep* Company* Huadong Pharmaceutical (000963): Performance maintains steady growth, innovation pipeline continues to advance
East China Pharmaceutical (000963): Innovation and progress in multiple fields, rich attention to engineering and medical and aesthetic flexibility
Huadong Pharmaceutical (000963) 2024 Third Quarterly Report Review: Pharmaceutical performance is outstanding, medical beauty is under slight pressure
East China Pharmaceutical (000963): Performance is in line with expectations, the industrial and micro sector is growing rapidly
East China Pharmaceutical (000963): Overall performance has maintained steady growth, and the innovation pipeline layout continues to be rich
East China Pharmaceutical (000963): Q2 performance slightly exceeded expectations, steady industrial growth and abundant reserves of medical and aesthetic products
East China Pharmaceutical (000963): Profit-side performance is impressive, and the overall profit contribution of the medical and aesthetic sector is steadily increasing
Huadong Pharmaceutical (000963): Steady growth in performance and increased innovation pipeline
Huadong Pharmaceutical (000963): Q2 performance exceeded expectations, innovation and transformation continued to be realized
Huadong Pharmaceutical (000963): Net profit slightly exceeded expectations, and BD continues to land
Huadong Pharmaceutical (000963): The results of the 24-year mid-year report slightly exceeded market expectations
Huadong Pharmaceutical (000963): 2Q24 profit growth accelerated
Huadong Pharmaceutical (000963): Profit growth slightly exceeds market expectations and continues to increase self-defense and CAR-T
East China Pharmaceutical (000963): Various sectors continue to grow steadily and the innovation pipeline layout continues to be rich
Huadong Pharmaceutical (000963): Performance growth slightly exceeds expectations and continues to expand R&D and innovation pipeline